Latest filing published 04 Sept 2026 for Editas Medicine, Inc., €1,857.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Linda Burkly is a declared insider of Editas Medicine, Inc., with filings sourced from SEC (Form 4). We count 13 filings; the first trade dates from 24 July 2023 and the latest from 3 September 2026.
Sales make up the whole of the open-market record (10 sales, €96k). Outside the open market, there are 3 share grants. 2026 to date brings no purchases and 4 sales.
The latest filing, published on 4 September 2026, reports an open-market sale of €1,857 in Editas Medicine, Inc. Typically, a trade is published a median of 1 day after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations